| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.097 | 0.2 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | -0.053 | 0.2 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.073 | 0.2 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.099 | 0.2 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.1 | 0.2 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | -0.096 | 0.2 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.2 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | -0.055 | 0.2 |
| mRNA | triptolide | CTRPv2 | pan-cancer | AAC | -0.055 | 0.2 |